Service de radio-oncologie, Centre Hospitalier Universitaire Habib Bourguiba, Sfax, Tunisia; Service de radio-oncologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Service de radio-oncologie, Département Valaisan d’Oncologie, Hôpital de Sion-CHCVs-RSV, Sion, Switzerland.
Swiss Med Wkly. 2013 May 28;143:w13780. doi: 10.4414/smw.2013.13780. eCollection 2013.
Surgery has historically been the standard of care for operable stage I non-small cell lung cancer (NSCLC). However, nearly one-quarter of patients with stage I NSCLC will not undergo surgery because of medical comorbidity or other factors. Stereotactic ablative radiotherapy (SABR) is the new standard of care for these patients. SABR offers high local tumour control rates rivalling the historical results of surgery and is generally well tolerated by patients with both peripheral and centrally located tumours. This article reviews the history of SABR for stage I NSCLC, summarises the currently available data on efficacy and toxicity, and describes some of the currently controversial aspects of this treatment.
手术一直是可手术治疗 I 期非小细胞肺癌（NSCLC）的标准治疗方法。然而，近四分之一的 I 期 NSCLC 患者由于合并症或其他因素而无法接受手术。立体定向消融放疗（SABR）是这些患者的新标准治疗方法。SABR 提供了与手术历史结果相媲美的高局部肿瘤控制率，并且通常被患有周围和中央肿瘤的患者很好地耐受。本文回顾了 SABR 治疗 I 期 NSCLC 的历史，总结了目前关于疗效和毒性的可用数据，并描述了这种治疗方法的一些目前存在争议的方面。
